描述

相關類別

研究領域 >> 癌癥

靶點

EGFR:370 pM (IC50)

參考文獻

[1]. Discafani CM, et al. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochem Pharmacol. 1999 Apr 15;57(8):917-25.

[2]. Sweeney WE, et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000 Jan;57(1):33-40.

[3]. Greulich H, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov;2(11):e313.

[4]. Kobayashi S, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005 Aug 15;65(16):7096-101.

密度

1.6±0.1 g/cm3

分子式

C18H13BrN4O

分子量

381.226

質量

380.027252

PSA

70.40000

LogP

4.68

折射率

1.755

N-{4-[(3-Bromophenyl)amino]-6-quinazolinyl}-2-butynamide

N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide

CL-387,785

N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide

N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide

2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-

EKI-785

UNII-B4W27J1Z8B

4-anilinoquinazoline deriv. 1

CL-387785